By Robb M. Stewart
TG Therapeutics Is targeting a further jump in revenue this year after swinging to a profit in the latest quarter with higher sales of its flagship treatment for relapsing forms of multiple sclerosis.
The commercial-stage biopharmaceutical company swung to a profit of $23.3 million, or 15 cents a share, from a year-earlier loss of $14.4 million, or 10 cents a share. Analysts polled by FactSet had penciled in per-share earnings of 16 cents for the quarter.
Revenue more than doubled to $108.2 million from $44 million in the same period last year.
Product revenue for the quarter totaled $107.3 million, primarily reflecting $103.6 million in sales of Briumvi, a monoclonal antibody used as a multiple sclerosis treatment.
A monoclonal antibody is a type of protein that can bind to certain targets in the body. Multiple sclerosis is a long-lasting disease of the central nervous system.
TG Therapeutics is targeting global revenue in 2025 of about $540 million, including Briumvi U.S. product revenue of roughly $525 million. Analysts were expected revenue this year of $534.4 million, after the company recorded 2024 revenue of $329 million.
Full-year operating expense is expected to be about $300 million, excluding non-cash compensation, the company said.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
March 03, 2025 07:47 ET (12:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。